Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18300720 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18300719 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6563624 | 0.88 | CYP1A2 (0.78) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6563634 | 0.88 | CYP1A2 (0.78) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11435631 | 0.75 | CYP1A2 (0.80) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29426430 | 0.75 | CYP1A2 (0.80) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27657952 | 0.75 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27657951 | 0.74 | KMT2A (0.58) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6936903 | 0.74 | CYP1B1 (0.72) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5261510 | 0.72 | KMT2A (0.56) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148401-A1 | Compounds and Methods of Use Thereof for Treating Tumors | GEORGETOWN UNIVERSITY | 2018-05-31 | — | — | US | disclosed |
| US-20180148401-A1 | Compounds and Methods of Use Thereof for Treating Tumors | GEORGETOWN UNIVERSITY | 2018-05-31 | — | — | US | disclosed |
| US-9695108-B2 | Compounds and methods of use thereof for treating tumors | GEORGETOWN UNIVERSITY (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695108-B2 | Compounds and methods of use thereof for treating tumors | GEORGETOWN UNIVERSITY (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | American University of Cairo (EG) | 2016-12-15 | — | — | US | disclosed |
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | American University of Cairo (EG) | 2016-12-15 | — | — | US | disclosed |
| US-20150344440-A1 | Compounds and Methods of Use Thereof for Treating Tumors | GEORGETOWN UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| US-20150344440-A1 | Compounds and Methods of Use Thereof for Treating Tumors | GEORGETOWN UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| WO-2014032019-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING TUMORS | GEORGETOWN UNIVERSITY (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361311-A1 | LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN | CD81, HAVCR2, CTRL | CYP1A2 406/4885CYP2D6 60/4885CYP3A4 94/4885 |
| US-20150344440-A1 | Compounds and Methods of Use Thereof for Treating Tumors | VHL, TP53, RHOA | CYP1A2 4173/4885CYP2D6 4178/4885CYP3A4 4425/4885 |
| US-20180148401-A1 | Compounds and Methods of Use Thereof for Treating Tumors | VHL, TP53, RHOA | CYP1A2 4173/4885CYP2D6 4178/4885CYP3A4 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.